Basic Study Design

  • Lawrence M. Friedman
  • Curt D. Furberg
  • David L. DeMets


The foundations for the design of controlled experiments were established for agricultural application. They are described in several classical statistics textbooks [1–4]. From these sources evolved the basic design of controlled clinical trials.


Historical Control Adaptive Design Pragmatic Trial Superiority Trial Noninferiority Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Fisher RA. Statistical Methods for Research Workers. Edinburgh: Oliver and Boyd, 1925.Google Scholar
  2. 2.
    Fisher RA. The Design of Experiments. Edinburgh: Oliver and Boyd, 1935.Google Scholar
  3. 3.
    Cochran WG, Cox GM Experimental Designs (2nd edition). New York: John Wiley and Sons, 1957.MATHGoogle Scholar
  4. 4.
    Cox DR. Planning of Experiments. New York: John Wiley and Sons, 1958.MATHGoogle Scholar
  5. 5.
    Bull JP. The historical development of clinical therapeutic trials. J Chronic Dis 1959;10:218–248.Google Scholar
  6. 6.
    Eliot MM. The control of rickets: preliminary discussion of the demonstration in New Haven. JAMA 1925;85:656–663.Google Scholar
  7. 7.
    Hill AB. Observation and experiment. N Engl J Med 1953;248:995–1001.Google Scholar
  8. 8.
    Macfarlane G. Howard Florey: The Making of a Great Scientist. Oxford: Oxford University Press, 1979, pp 11–12.Google Scholar
  9. 9.
    Gocke DJ. Fulminant hepatitis treated with serum containing antibody to Australia antigen. N Engl J Med 1971;284:919.Google Scholar
  10. 10.
    Acute Hepatic Failure Study Group. Failure of specific immunotherapy in fulminant type B hepatitis. Ann Intern Med 1977;86:272–277.Google Scholar
  11. 11.
    Snow JB Jr, Kimmelman CP. Assessment of surgical procedures for Ménière’s disease. Laryngoscope 1979;89:737–747.Google Scholar
  12. 12.
    Armitage P, Berry G, Matthews JNS. Statistical Methods in Medical Research (4th edition). Malden, MA: Blackwell Publishing, 2002.Google Scholar
  13. 13.
    Brown BW, Hollander M. Statistics: A Biomedical Introduction. New York: John Wiley and Sons, 1977.Google Scholar
  14. 14.
    Feinstein AR. Clinical Biostatistics. St Louis: The C.V. Mosby Company, 1977.Google Scholar
  15. 15.
    MacMahon B, Trichopoulos D. Epidemiology: Principles and Methods (2nd edition). Lippincott Williams & Wilkins, 1996.Google Scholar
  16. 16.
    Lilienfeld DE, Stolley PD. Foundations of Epidemiology (3rd edition). New York: Oxford University Press, 1994.Google Scholar
  17. 17.
    Srivastava JN (ed.). A Survey of Statistical Design and Linear Models. Amsterdam: North-Hollard, 1975.MATHGoogle Scholar
  18. 18.
    Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. 1. Introduction and design. Br J Cancer 1976;34:585–612.Google Scholar
  19. 19.
    Brown BW Jr. Statistical controversies in the design of clinical trials – some personal views. Control Clin Trials 1980;1:13–27.Google Scholar
  20. 20.
    Pocock SJ. Allocation of patients to treatment in clinical trials. Biometrics 1979;35:183–197.Google Scholar
  21. 21.
    Brown BW Jr. The crossover experiment for clinical trials. Biometrics 1980;36:69–79.MATHGoogle Scholar
  22. 22.
    Hennekens CH, Buring JC. Epidemiology in Medicine. SL Mayrent (ed.). Boston: Little, Brown, 1987.Google Scholar
  23. 23.
    Byar DP. Some statistical considerations for design of cancer prevention trials. Prev Med 1989;18:688–699.Google Scholar
  24. 24.
    Geller NL (ed.). Advances in Clinical Trial Biostatistics. New York: Marcel Dekker, 2003.Google Scholar
  25. 25.
    Piantadosi S. Clinical Trials: A Methodologic Perspective (2nd edition). New York: John Wiley and Sons, 2005.Google Scholar
  26. 26.
    Machin D, Day S, Green S. Textbook of Clinical Trials (2nd edition). West Sussex: John Wiley and Sons, 2006.Google Scholar
  27. 27.
    Green S, Benedetti J, Crowley J. Clinical Trials in Oncology (2nd edition). Boca Raton: CRC Press, 2002.Google Scholar
  28. 28.
    Hulley SB, Cummings SR, Browner WS, et al. Designing Clinical Research: An Epidemiologic Approach (3rd edition). New York: Wolters Kluwer, 2006.Google Scholar
  29. 29.
    Meinert CL, Clinical Trials: Design, Conduct and Analysis. New York: Oxford University Press, 1986.Google Scholar
  30. 30.
    Cook TD, DeMets DL (eds.). Introduction to Statistical Methods for Clinical Trials. Boca Raton: Chapman & Hall/CRC, Taylor & Francis Group, LLC, 2008.MATHGoogle Scholar
  31. 31.
    Chow S-C, Shao J. Statistics in Drug Research: Methodologies and Recent Developments. New York: Marcel Dekker, 2002.Google Scholar
  32. 32.
    Green SB, Byar DP. Using observational data from registries to compare treatments: the fallacy of omnimetrics. Stat Med 1984;3:361–373.Google Scholar
  33. 33.
    Gehan EA, Freireich EJ. Non-randomized controls in cancer clinical trials. N Engl J Med 1974;290:198–203.Google Scholar
  34. 34.
    Weinstein MC. Allocation of subjects in medical experiments. N Engl J Med 1974;291:1278–1285.Google Scholar
  35. 35.
    Byar DP, Simon RM, Friedewald WT, et al. Randomized clinical trials: perspectives on some recent ideas. N Engl J Med 1976;295:74–80.Google Scholar
  36. 36.
    Sapirstein W, Alpert S, Callahan TJ. The role of clinical trials in the Food and Drug Administration approval process for cardiovascular devices. Circulation 1994;89:1900–1902.Google Scholar
  37. 37.
    Hlatky MA. Perspective: evidence-based use of cardiac procedures and devices. N Engl J Med 2004;350:2126–2128.Google Scholar
  38. 38.
    Chalmers TC, Matta RJ, Smith H, Kunzier AM. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977;297:1091–1096.Google Scholar
  39. 39.
    Peto R. Clinical trial methodology. Biomedicine (Special issue) 1978;28:24–36.Google Scholar
  40. 40.
    Goldman L, Feinstein AR. Anticoagulants and myocardial infarction: the problems of pooling, drowning, and floating. Ann Intern Med 1979;90:92–94.Google Scholar
  41. 41.
    Grace ND, Muench H, Chalmers TC. The present status of shunts for portal hypertension in cirrhosis. Gastroenterology 1966;50:684–691.Google Scholar
  42. 42.
    Sacks H, Chalmers TC, Smith H Jr. Randomized versus historical controls for clinical trials. Am J Med 1982;72:233–240.Google Scholar
  43. 43.
    Sacks HS, Chalmers TC, Smith H Jr. Sensitivity and specificity of clinical trials: randomized v historical controls. Arch Intern Med 1983;143:753–755.Google Scholar
  44. 44.
    Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983;309:1358–1361.Google Scholar
  45. 45.
    Ingelfinger FJ. The randomized clinical trial (editorial). N Engl J Med 1972;287:100–101.Google Scholar
  46. 46.
    Zelen M. A new design for randomized clinical trials. N Engl J Med 1979;300:1242–1245.Google Scholar
  47. 47.
    Anbar D. The relative efficiency of Zelen’s prerandomization design for clinical trials. Biometrics 1983;39:711–718.Google Scholar
  48. 48.
    Ellenberg SS. Randomization designs in comparative clinical trials. N Engl J Med 1984;310:1404–1408.Google Scholar
  49. 49.
    Zelen M. Randomized consent designs for clinical trials: an update. Stat Med 1990;9:645–656.Google Scholar
  50. 50.
    Gehan EA. The evaluation of therapies: historical control studies. Stat Med 1984;3:315–324.Google Scholar
  51. 51.
    Lasagna L. Historical controls: the practitioner’s clinical trials. N Engl J Med 1982;307:1339–1340.Google Scholar
  52. 52.
    Moertel CG. Improving the efficiency of clinical trials: a medical perspective. Stat Med 1984;3:455–465.Google Scholar
  53. 53.
    Pocock SJ. Letter to the editor. Br Med J 1977;1:1661.Google Scholar
  54. 54.
    Veterans Administration Cooperative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011–1017.Google Scholar
  55. 55.
    Packer M, O’Connor CM, Ghali JK, et al. for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107–1114.Google Scholar
  56. 56.
    Thackray S, Witte K, Clark AL, Cleland JGF. Clinical trials update: OPTIME-CHF, PRAISE-2, ALLHAT. Eur J Heart Fail 2000;2:209–212.Google Scholar
  57. 57.
    Havlik RJ, Feinleib M (eds.). Proceedings of the Conference on the Decline in Coronary Heart Disease Mortality. Washington, D.C.: NIH Publication No. 79–1610, 1979.Google Scholar
  58. 58.
    U.S. Department of Health and Human Services. Health, United States, 2008, With Special Feature on the Health of Young Adults. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics.
  59. 59.
    Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360–381.Google Scholar
  60. 60.
    Castro KG, Ward JW, Slutsker L, et al. 1993 revised classification system for HIV infection and expanded surveillance case definitions for AIDS among adolescents and adults. MMWR Recomm Rep, December 18, 1992;41(RR–17).Google Scholar
  61. 61.
    Current trends update: trends in AIDS diagnosis and reporting under the expanded surveillance definition for adolescents and adults – United States, 1993. MMWR Weekly 1994;43:826–831.Google Scholar
  62. 62.
    Rosenberg HM, Klebba AJ. Trends in cardiovascular mortality with a focus on ischemic heart disease: United States, 1950-1976. In Havlik R, Feinleib M (eds.). Proceedings of the Conference on the Decline in Coronary Heart Disease Mortality. Washington, D.C.: NIH Publication No. 79-1610, 1979.Google Scholar
  63. 63.
    National Heart, Lung, and Blood Institute. Morbidity and Mortality Chartbook on Cardiovascular, Lung, and Blood Diseases. National Heart, Lung, and Blood Institute,U.S. Department of Health and Human Services, Public Health Service. May 1994.Google Scholar
  64. 64.
    Bailar JC III, Louis TA, Lavori PW, Polansky M. Studies without internal controls. N Engl J Med 1984;311:156–162.Google Scholar
  65. 65.
    Dustan HP, Schneckloth RE, Corcoran AC, Page IH. The effectiveness of long-term treatment of malignant hypertension. Circulation 1958;18:644–651.Google Scholar
  66. 66.
    Bjork S, Sannerstedt R, Angervall G, Hood B. Treatment and prognosis in malignant hypertension: clinical follow-up study of 93 patients on modern medical treatment. Acta Med Scand 1960;166:175–187.Google Scholar
  67. 67.
    Bjork S, Sannerstedt R, Falkheden T, Hood B. The effect of active drug treatment in severe hypertensive disease: an analysis of survival rates in 381 cases on combined treatment with various hypotensive agents. Acta Med Scand 1961;169:673–689.Google Scholar
  68. 68.
    Starmer CF, Lee KL, Harrell FE, Rosati RA. On the complexity of investigating chronic illness. Biometrics 1980;36:333–335.Google Scholar
  69. 69.
    Hlatky MA, Lee KL, Harrell FE Jr, et al. Tying clinical research to patient care by use of an observational database. Stat Med 1984;3:375–387.Google Scholar
  70. 70.
    Hlatky MA, Califf RM, Harrell FE Jr, et al. Clinical judgment and therapeutic decision making. J Am Coll Cardiol 1990;15:1–14.Google Scholar
  71. 71.
    Moon TE, Jones SE, Bonadonna G, et al. Using a database of protocol studies to evaluate therapy: a breast cancer example. Stat Med 1984;3:333–339.Google Scholar
  72. 72.
    Anderson C. Measuring what works in health care. Science 1994;263:1080–1082.Google Scholar
  73. 73.
    Klungel OH, Heckbert SR, Longstreth WT, et al. Antihypertensive drug therapies and the risk of ischemic stroke. Arch Intern Med 2001;161:37–43.Google Scholar
  74. 74.
    Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475–481.Google Scholar
  75. 75.
    Byar DP. Why databases should not replace randomized clinical trials. Biometrics 1980;36:337–342.Google Scholar
  76. 76.
    Dambrosia JM, Ellenberg JH. Statistical considerations for a medical database. Biometrics 1980;36:323–332.Google Scholar
  77. 77.
    Sheldon TA. Please bypass the PORT. Br Med J 1994;309:142–143.Google Scholar
  78. 78.
    Mantel N. Cautions on the use of medical databases. Stat Med 1983;2:355–362.Google Scholar
  79. 79.
    James KE, Forrest WH Jr, Rose RL. Crossover and noncrossover designs in four-point parallel line analgesic assays. Clin Pharmacol Ther 1985;37:242–252.Google Scholar
  80. 80.
    Carriere KC. Crossover designs for clinical trials. Stat Med 1994;13:1063–1069.Google Scholar
  81. 81.
    Koch GG, Amara IA, Brown BW Jr, et al. A two-period crossover design for the comparison of two active treatments and placebo. Stat Med 1989;8:487–504.Google Scholar
  82. 82.
    Fleiss JL. A critique of recent research on the two treatment crossover design. Control Clin Trials 1989;10:237–243.Google Scholar
  83. 83.
    Woods JR, Williams JG, Tavel M. The two-period crossover design in medical research. Ann Intern Med 1989;110:560–566.Google Scholar
  84. 84.
    Louis TA, Lavori PW, Bailar JC III, Polansky M. Crossover and self-controlled designs in clinical research. N Engl J Med 1984;310:24–31.Google Scholar
  85. 85.
    International Conference on Harmonisation: E9 Statistical principles for clinical trials.
  86. 86.
    Grizzle JE. The two period change-over design and its use in clinical trials. Biometrics 1965;21:467–480.Google Scholar
  87. 87.
    Fleiss JL, Wallenstein S, Rosenfeld R. Adjusting for baseline measurements in thetwo-period crossover study: a cautionary note. Control Clin Trials 1985;6:192–197.Google Scholar
  88. 88.
    Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979;8:7–20.Google Scholar
  89. 89.
    Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-Up Program 1 Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562–2571.Google Scholar
  90. 90.
    Stamler R, Stamler J, Grimm R, et al. Nutritional therapy for high blood pressure-Final report of a four-year randomized controlled trial – The Hypertension Control Program. JAMA 1987;257:1484–1491.Google Scholar
  91. 91.
    Report of the Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;316:989–994.Google Scholar
  92. 92.
    Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000;11:1910–1917.Google Scholar
  93. 93.
    Black DM, Schwartz AV, Ensrud KE, et al, for the FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927–2938.Google Scholar
  94. 94.
    Montgomery AA, Peters TJ, Little P. Design, analysis and presentation of factorial randomized controlled trials. BMC Med Res Methodol 2003;3:26; doi: 10.1186/1471-2288-3-26.Google Scholar
  95. 95.
    The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978;299:53–59.Google Scholar
  96. 96.
    ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomized study of streptokinase vs plasminogen activator vs anistrephase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753–770.Google Scholar
  97. 97.
    Stampfer MJ, Buring JE, Willett W, et al. The 2 x 2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians. Stat Med 1985;4:111–116.Google Scholar
  98. 98.
    Design of the Women’s Health Initiative clinical trial and observational study. The Women’s Health Initiative Study Group. Control Clin Trials 1998;19:61–109.Google Scholar
  99. 99.
    McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA 2003;289:2545–2553.Google Scholar
  100. 100.
    Byar DP, Herzberg AM, Tan W-Y. Incomplete factorial designs for randomized clinical trials. Stat Med 1993;12:1629–1641.Google Scholar
  101. 101.
    Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med 2008;358:2545–2559.Google Scholar
  102. 102.
    Fletcher DJ, Lewis SM, Matthews JNS. Factorial designs for crossover clinical trials. Stat Med 1990;9:1121–1129.Google Scholar
  103. 103.
    Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.Google Scholar
  104. 104.
    The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701–1712.Google Scholar
  105. 105.
    Brittain E, Wittes J. Factorial designs in clinical trials: the effects of non-compliance and subadditivity. Stat Med 1989;8:161–171.Google Scholar
  106. 106.
    Hayes RJ, Moulton LH. Cluster Randomized Trials: A Practical Approach. Chapman & Hall/CRC, Taylor & Francis Group, 2009.Google Scholar
  107. 107.
    Donner A, Birkett N, Buck C. Randomization by cluster: sample size requirements and analysis. Am J Epidemiol 1981;114:906–914.Google Scholar
  108. 108.
    Armitage P. The role of randomization in clinical trials. Stat Med 1982;1:345–352.Google Scholar
  109. 109.
    Simon R. Composite randomization designs for clinical trials. Biometrics 1981;37:723–731.MATHGoogle Scholar
  110. 110.
    Cornfield J. Randomization by group: a formal analysis. Am J Epidemiol 1978;108:100–102.Google Scholar
  111. 111.
    Zucker DM, Lakatos E, Webber LS, et al. Statistical design of the Child and Adolescent Trial for Cardiovascular Health (CATCH): implications of cluster randomization. Control Clin Trials 1995;16:96–118.Google Scholar
  112. 112.
    Vijayaraghavan K, Radhaiah G, Prakasam BS, et al. Effect of massive dose vitamin A on morbidity and mortality in Indian children. Lancet 1990;336:1342–1345.Google Scholar
  113. 113.
    Luepker RV, Raczynski JM, Osganian S, et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: the Rapid Early Action for Coronary Treatment (REACT) trial. JAMA 2000;284:60–67.Google Scholar
  114. 114.
    Farquhar JW, Fortmann SP, Flora JA, et al. Effects of community-wide education on cardiovascular disease risk factors. The Stanford Five-City Project. JAMA 1990;264:359–365.Google Scholar
  115. 115.
    Gail MH, Byar DP, Pechacek TF, Corle DK, for COMMIT Study Group. Aspects of statistical design for the Community Intervention Trial for Smoking Cessation. Control Clin Trials 1992;13:6–21.Google Scholar
  116. 116.
    Sismanidis C, Moulton LH, Ayles H, et al. Restricted randomization of ZAMSTAR: a 2x2 factorial cluster randomized trial. Clin Trials 2008;5:316–327.Google Scholar
  117. 117.
    Pocock SJ. The combination of randomized and historical controls in clinical trials. J Chronic Dis 1976;29:175–188.Google Scholar
  118. 118.
    Machin D. On the possibility of incorporating patients from nonrandomising centres into a randomised clinical trial. J Chronic Dis 1979;32:347–353.Google Scholar
  119. 119.
    Gruppo Italiano per lo Studio della Streptochinasi nell’ Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;i:397–402.Google Scholar
  120. 120.
    The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673–682; correction N Engl J Med 1994;331:277.Google Scholar
  121. 121.
    The Digitalis Investigation Group. Rationale, design, implementation, and baseline characteristics of patients in the DIG Trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Control Clin Trials 1996;17:77–97.Google Scholar
  122. 122.
    MICHELANGELO OASIS 5 Steering Committee. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 2005;150:1107–1114.Google Scholar
  123. 123.
    Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624–1632.Google Scholar
  124. 124.
    March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005;162:836–846.Google Scholar
  125. 125.
    Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009;62:464–475.Google Scholar
  126. 126.
    Blackwelder WC. “Proving the null hypothesis” in clinical trials. Control Clin Trials 1982;3:345–353.Google Scholar
  127. 127.
    Hung JHM, Wang SJ, Tsong Y, et al. Some fundamental issues with non-inferiority testing in active controlled trials. Stat Med 2003;30:213–225.Google Scholar
  128. 128.
    Fleming TR. Current issues in non-inferiority trials. Stat Med 2008;27:317–332.MathSciNetGoogle Scholar
  129. 129.
    D’Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues – the encounters of academic consultants in statistics. Stat Med 2003;22:169–186.Google Scholar
  130. 130.
    Kaul S, Diamond GA. Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials. Prog Cardiovasc Dis 2007;49:284–299.Google Scholar
  131. 131.
    SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690–698.Google Scholar
  132. 132.
    Pocock SJ, Ware JH. Translating statistical findings into plain English. Lancet 2009;373:1926–1928.Google Scholar
  133. 133.
    Trivedi MH, Rush AJ, Wisniewski SR, et al, for the STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28–40.Google Scholar
  134. 134.
    Murphy SA, Oslin DW, Rush AJ, Zhu J, for MCATS. Methodological challenges in constructing effective treatment sequences for chronic psychiatric disorders (Perspective). Neuropsychopharmacology 2007;32:257–262.Google Scholar
  135. 135.
    Lavori PW, Dawson D. Improving the efficiency of estimation in randomized trials of adaptive treatment strategies. Clin Trials 2007;4:297–308.Google Scholar

Copyright information

© Springer New York 2010

Authors and Affiliations

  • Lawrence M. Friedman
    • 1
  • Curt D. Furberg
    • 2
  • David L. DeMets
    • 3
  1. 1.BethesdaUSA
  2. 2.School of MedicineWake Forest UniversityWinston-SalemUSA
  3. 3.Department of Biostatistics & Medical InformaticsUniversity of WisconsinMadisonUSA

Personalised recommendations